Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT05126472 trial: what clinicians have said so far
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
- NCT05126472 ↗
- Recruiting
- Memorial Sloan Kettering Cancer Center
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT05126472 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05126472 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- Phase I/II Study Evaluating the Safety and Tolerability of Locally Administered Anti-CD40 Agonist Antibody (2141-V11) in Subjects With Bladder Cancer
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Non-muscle Invasive Bladder Cancer
- Interventions
- anti-CD40 antibody 2141-V11; anti-CD40 antibody 2141-V11; anti-CD40 antibody 2141-V11; Intravesical Gemcitabine; Intravesical Gemcitabine with anti-CD40 antibody 2141-V11
- Arms
- (Cohort A) anti-CD40 antibody 2141-V11 · Experimental
- (Cohort B) Part 1 2141-V11, a fixed dose of 10mg , Part 2 Gemcitabine · Experimental
- (Cohort C) expansion cohort 10 mg of 2141-V11 · Experimental
- Enrollment
- 115 (estimated)
- Primary outcomes
- MTD/RP2D (Cohort A)
- Reported number of adverse events from baseline (start of 2141-V11 administration) up until the last follow-up visit after 2141-V11 administration (Cohort B)
- recurrence-free survival (RFS) Cohort B Part 2
- Progression of disease
- Sponsor
- Memorial Sloan Kettering Cancer Center with Pin Down Bladder Cancer Research Foundation, Rockefeller University
- Start
- Nov 8, 2021
- Primary completion
- Nov 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05126472 · updated Nov 16, 2026